RQ-3033

N/A

Report date: 2026/05/13 09:07:52

Base Information

Drug NameRQ-3033
Drug Alias Name新型冠状病毒变异株mRNA疫苗（OmicronXBB.1.5）RQ-3033RQ3033
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccineVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaCoronavirus Disease 2019 (COVID-19)
Original Approved Country/TerritoryMainland China
Original Approved Date2023/12/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Rnacure Biopharma Co LtdFudan UniversityWalvax Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWalvax Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A